Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years

the ONA take:

An analysis of data from the Surveillance, Epidemiology, and End Results–Medicare database has found that sunitinib and sorafenib may be associated with an increased risk of cardiovascular events, particularly stroke, in older patients with renal cell carcinoma (RCC).

Sorafenib and sunitinib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for the treatment of RCC.

The population-based, observational cohort study analyzed patients ages 66 years or older with RCC diagnosed between 2000 and 2009. The researchers examined incidence of cardiovascular events, including congestive heart failure and cardiomyopathy (CHF/CM), acute myocardial infarction (AMI), stroke, and cardiovascular deaths through December 2010.

Of the 670 patients who received sorafenib or sunitinib, 171 had experienced a cardiovascular event. Use of either of the drugs was associated with an increased risk of cardiovascular events and especially stroke compared with 788 patients with advanced RCC diagnosed from 2007 to 2009 who did not receive either agent.

Subgroup analyses revealed that patients ages 66 to 74 years at diagnosis had the highest increased risk of stroke associated with use of sorafenib or sunitinib, or both.

Joint statement offers new recommendations for treating patients with cardiovascular conditions
Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma.
READ FULL ARTICLE From Wiley Online Library
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs